Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is associated with aggressive tumor behavior and poor prognosis. Most patients with PDAC present with an advanced disease stage and treatment-resistant tumors. The lack of noninvasive tests for PDAC diagnosis and su...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-03, Vol.13 (5), p.1071 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1071 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Giannis, Dimitrios Moris, Dimitrios Barbas, Andrew S |
| description | Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is associated with aggressive tumor behavior and poor prognosis. Most patients with PDAC present with an advanced disease stage and treatment-resistant tumors. The lack of noninvasive tests for PDAC diagnosis and survival prediction mandates the identification of novel biomarkers. The early identification of high-risk patients and patients with PDAC is of utmost importance. In addition, the identification of molecules that are associated with tumor biology, aggressiveness, and metastatic potential is crucial to predict survival and to provide patients with personalized treatment regimens. In this review, we summarize the current literature and focus on newer biomarkers, which are continuously added to the armamentarium of PDAC screening, predictive tools, and prognostic tools. |
| doi_str_mv | 10.3390/cancers13051071 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7959127</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2498669838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-c41fba3f4167b5f9142620bf56cbdee34c91602f7de160da1c975d35b8e997713</originalsourceid><addsrcrecordid>eNpdkU0vBTEUhhshCNZ20sTGwqUfM-3UQsL1mRAWrJtO5wxlbks7c8W_18sl6KKnzXnO2_f0ILRJyR7niuxb4y3ERDkpKZF0Aa0yItlICFUs_jqvoI2UnkhenFMp5DJa4bwijBdkFT2fOPPgQ-qd3cW3ERpnezcFbHyTr2GewtehAzt0JuJjFyYmPud3sfP4NluIYGbI-NPNAT7y-GYKcergDbch4nHnvLPO-LSOllrTJdiYxzV0f3Z6N74YXd2cX46Prka2YLTPO21rw9uCClmXraIFE4zUbSls3QDwwioqCGtlAzk2hloly4aXdQVKSUn5Gjr80n0Z6gk0FnwfTadfosvO33UwTv_NePeoH8JUS1UqymQW2JkLxPA6QOr1xCULXWc8hCFpVpKqFExUVUa3_6FPYYg-t6dZoar8_xWfUftflI0hpQjtjxlK9GyW-t8sc8XW7x5--O_J8Q9wCpyh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2498669838</pqid></control><display><type>article</type><title>Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Giannis, Dimitrios ; Moris, Dimitrios ; Barbas, Andrew S</creator><creatorcontrib>Giannis, Dimitrios ; Moris, Dimitrios ; Barbas, Andrew S</creatorcontrib><description>Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is associated with aggressive tumor behavior and poor prognosis. Most patients with PDAC present with an advanced disease stage and treatment-resistant tumors. The lack of noninvasive tests for PDAC diagnosis and survival prediction mandates the identification of novel biomarkers. The early identification of high-risk patients and patients with PDAC is of utmost importance. In addition, the identification of molecules that are associated with tumor biology, aggressiveness, and metastatic potential is crucial to predict survival and to provide patients with personalized treatment regimens. In this review, we summarize the current literature and focus on newer biomarkers, which are continuously added to the armamentarium of PDAC screening, predictive tools, and prognostic tools.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13051071</identifier><identifier>PMID: 33802340</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenocarcinoma ; Antigens ; Asymptomatic ; Biomarkers ; Cell adhesion & migration ; Deoxyribonucleic acid ; Disease ; DNA ; DNA methylation ; Gene expression ; Malignancy ; Medical prognosis ; Metastases ; MicroRNAs ; Mutation ; Pancreatic cancer ; Pancreatitis ; Review ; Risk groups ; Survival ; Tumors ; Urine</subject><ispartof>Cancers, 2021-03, Vol.13 (5), p.1071</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-c41fba3f4167b5f9142620bf56cbdee34c91602f7de160da1c975d35b8e997713</citedby><cites>FETCH-LOGICAL-c421t-c41fba3f4167b5f9142620bf56cbdee34c91602f7de160da1c975d35b8e997713</cites><orcidid>0000-0002-5276-0699</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959127/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959127/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33802340$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giannis, Dimitrios</creatorcontrib><creatorcontrib>Moris, Dimitrios</creatorcontrib><creatorcontrib>Barbas, Andrew S</creatorcontrib><title>Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is associated with aggressive tumor behavior and poor prognosis. Most patients with PDAC present with an advanced disease stage and treatment-resistant tumors. The lack of noninvasive tests for PDAC diagnosis and survival prediction mandates the identification of novel biomarkers. The early identification of high-risk patients and patients with PDAC is of utmost importance. In addition, the identification of molecules that are associated with tumor biology, aggressiveness, and metastatic potential is crucial to predict survival and to provide patients with personalized treatment regimens. In this review, we summarize the current literature and focus on newer biomarkers, which are continuously added to the armamentarium of PDAC screening, predictive tools, and prognostic tools.</description><subject>Adenocarcinoma</subject><subject>Antigens</subject><subject>Asymptomatic</subject><subject>Biomarkers</subject><subject>Cell adhesion & migration</subject><subject>Deoxyribonucleic acid</subject><subject>Disease</subject><subject>DNA</subject><subject>DNA methylation</subject><subject>Gene expression</subject><subject>Malignancy</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>MicroRNAs</subject><subject>Mutation</subject><subject>Pancreatic cancer</subject><subject>Pancreatitis</subject><subject>Review</subject><subject>Risk groups</subject><subject>Survival</subject><subject>Tumors</subject><subject>Urine</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU0vBTEUhhshCNZ20sTGwqUfM-3UQsL1mRAWrJtO5wxlbks7c8W_18sl6KKnzXnO2_f0ILRJyR7niuxb4y3ERDkpKZF0Aa0yItlICFUs_jqvoI2UnkhenFMp5DJa4bwijBdkFT2fOPPgQ-qd3cW3ERpnezcFbHyTr2GewtehAzt0JuJjFyYmPud3sfP4NluIYGbI-NPNAT7y-GYKcergDbch4nHnvLPO-LSOllrTJdiYxzV0f3Z6N74YXd2cX46Prka2YLTPO21rw9uCClmXraIFE4zUbSls3QDwwioqCGtlAzk2hloly4aXdQVKSUn5Gjr80n0Z6gk0FnwfTadfosvO33UwTv_NePeoH8JUS1UqymQW2JkLxPA6QOr1xCULXWc8hCFpVpKqFExUVUa3_6FPYYg-t6dZoar8_xWfUftflI0hpQjtjxlK9GyW-t8sc8XW7x5--O_J8Q9wCpyh</recordid><startdate>20210303</startdate><enddate>20210303</enddate><creator>Giannis, Dimitrios</creator><creator>Moris, Dimitrios</creator><creator>Barbas, Andrew S</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5276-0699</orcidid></search><sort><creationdate>20210303</creationdate><title>Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians</title><author>Giannis, Dimitrios ; Moris, Dimitrios ; Barbas, Andrew S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-c41fba3f4167b5f9142620bf56cbdee34c91602f7de160da1c975d35b8e997713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma</topic><topic>Antigens</topic><topic>Asymptomatic</topic><topic>Biomarkers</topic><topic>Cell adhesion & migration</topic><topic>Deoxyribonucleic acid</topic><topic>Disease</topic><topic>DNA</topic><topic>DNA methylation</topic><topic>Gene expression</topic><topic>Malignancy</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>MicroRNAs</topic><topic>Mutation</topic><topic>Pancreatic cancer</topic><topic>Pancreatitis</topic><topic>Review</topic><topic>Risk groups</topic><topic>Survival</topic><topic>Tumors</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giannis, Dimitrios</creatorcontrib><creatorcontrib>Moris, Dimitrios</creatorcontrib><creatorcontrib>Barbas, Andrew S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giannis, Dimitrios</au><au>Moris, Dimitrios</au><au>Barbas, Andrew S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2021-03-03</date><risdate>2021</risdate><volume>13</volume><issue>5</issue><spage>1071</spage><pages>1071-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is associated with aggressive tumor behavior and poor prognosis. Most patients with PDAC present with an advanced disease stage and treatment-resistant tumors. The lack of noninvasive tests for PDAC diagnosis and survival prediction mandates the identification of novel biomarkers. The early identification of high-risk patients and patients with PDAC is of utmost importance. In addition, the identification of molecules that are associated with tumor biology, aggressiveness, and metastatic potential is crucial to predict survival and to provide patients with personalized treatment regimens. In this review, we summarize the current literature and focus on newer biomarkers, which are continuously added to the armamentarium of PDAC screening, predictive tools, and prognostic tools.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33802340</pmid><doi>10.3390/cancers13051071</doi><orcidid>https://orcid.org/0000-0002-5276-0699</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-03, Vol.13 (5), p.1071 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7959127 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Adenocarcinoma Antigens Asymptomatic Biomarkers Cell adhesion & migration Deoxyribonucleic acid Disease DNA DNA methylation Gene expression Malignancy Medical prognosis Metastases MicroRNAs Mutation Pancreatic cancer Pancreatitis Review Risk groups Survival Tumors Urine |
| title | Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A26%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic,%20Predictive%20and%20Prognostic%20Molecular%20Biomarkers%20in%20Pancreatic%20Cancer:%20An%20Overview%20for%20Clinicians&rft.jtitle=Cancers&rft.au=Giannis,%20Dimitrios&rft.date=2021-03-03&rft.volume=13&rft.issue=5&rft.spage=1071&rft.pages=1071-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13051071&rft_dat=%3Cproquest_pubme%3E2498669838%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2498669838&rft_id=info:pmid/33802340&rfr_iscdi=true |